Table 3.
Outcomes for visual analog, pain, stiffness, and functional scales at 6 and 12 months follow‐up
| Outcomes | HA group | MSC‐1 group | MSC‐2 group | Difference between treatments a | Multiple comparison b |
|---|---|---|---|---|---|
| At 6 months | |||||
| WOMAC | |||||
| Total | 18.6 ± 14.7 | 13.8 ± 9.2 | 8.3 ± 5.1 | .2 | |
| A. Pain (0–20) | 4.2 ± 3.8 | 2.1 ± 1.4 | 2.4 ± 1.7 | .36 | |
| B. Stiffness (0–8) | 1.1 ± 1.8 | 1.4 ± 1.2 | 0.9 ± 0.9 | .54 | |
| C. Function (0–68) | 13.3 ± 6.9 | 10.3 ± 7.2 | 5 ± 3.1 | .07 | |
| VAS 0–100, mm | 28 ± 8.7 | 12 ± 7.5 | 10.8 ± 7.8 | .09 | |
| At 12 months | |||||
| WOMAC | |||||
| Total | 15.2 ± 11 | 14.9 ± 12.7 | 4.2 ± 3.9 | .04 | HA vs. MSC‐2 .05 |
| A. Pain (0–20) | 4.3 ± 3.5 | 3.7 ± 2.6 | 1.1 ± 1.3 | .04 | HA vs. MSC‐2 .04 |
| B. Stiffness (0–8) | 1.7 ± 1.4 | 1.7 ± 2.1 | 0.6 ± 0.8 | .14 | |
| C. Function (0–68) | 9.2 ± 9.4 | 9.5 ± 7.4 | 2.6 ± 2.3 | .08 | |
| VAS 0–100, mm | 22.1 ± 9.8 | 13.3 ± 8.4 | 2.4 ± 2.1 | .02 | HA vs. MSC‐2 .03 |
Data are presented as mean ± SD.
Bolded p values are statistically significant.
a p value of Kruskal‐Wallis one‐way analysis of variance‐by‐ranks.
b p value of multiple comparison of mean ranks.
Abbreviations: HA, hyaluronic acid; MSC, mesenchymal stromal cells; VAS, visual analog scale; WOMAC, Western Ontario and Mc Master Universities Arthritis Index.